Opinion

Video

Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies

Author(s):

John Marshall, MDAl B. Benson III, MD, FACP, FACCC, FASCO

Oncology experts evaluate the influence of fruquintinib on current treatment protocols, drawing insights from the FRESCO and FRESCO-2 clinical studies.

  1. Briefly comment on the impact of fruquintinib on your current treatment paradigm based on the FRESCO (Li, et al. JAMA, 2018) and FRESCO-2 (Dasari, et al. Lancet, 2023) studies.
    1. How does the MOA compare to regorafenib or other VEGF inhibitors?

Related Videos
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
1 KOL is featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
A panel of 5 experts on CLL
Related Content
Sheela Rao, MD, MBBS, FRCP, of Royal Marsden Hospital NHS Foundation Trust
September 14th 2024

Retifanlimab Plus Carboplatin and Paclitaxel Offers PFS Benefit in Recurrent/Metastatic SCAC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Ben Zeskind, PhD, MBA
September 13th 2024

IMM-1-104 and Chemo Combination Elicit Responses in First-Line Pancreatic Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

FDA
September 5th 2024

FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma

Jennifer R. Eads, MD, physician lead of GI Cancer Research and director of the National Clinical Trials Network for Abramson Cancer Center at the University of Pennsylvania; and a professor of clinical medicine (hematology-oncology) at Penn Medicine in the Perelman Center for Advanced Medicine
August 31st 2024

Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma